New Chemo - Free Immunotherapy Options For NS...

Reviewing the hot-off-the press publication of PATINA, palbociclib in HER-2 amplified breast cancer along with endocrine therapy and HER-2 targeted antibodies. 

We review the recent ASCENT-04/Keynote-D19 publication of sacituzuab govitecan + pembrolizumab for PD-L1 CPS of 10% and above TNBC compared to chemo + pembrolizumab alone. Also, a quick recap of ASCO GI earlier this month with mentions of zanidatamab and zolbetuximab. Finally, a ...  Show more

In our previous episode, we covered the revised FIGO ovarian cancer staging which now includes fallopian tube and peritoneal malignancies. In this episode, we will cover the FIGO guidelines regarding the management of OVFTP cancer. What role do PARP inhibitors play? Does treatmen ...  Show more

The latest Oncology Decoded discussion with Manojkumar Bupathi, MD, MS, executive cochair of the Genitourinary Cancer Research Executive Committee at Sarah Cannon Research Institute (SCRI) and medical oncologist with Rocky Mountain Cancer Centers specializing in solid tumors and ...  Show more

This week’s episode  is part 2 of 2024 updates focusing on treatment options for localized breast cancer. We will discuss important details on radiation, as well as therapies based on ER/PR/her2 receptor status. We are honored to have Dr. Eleonora Teplinsky, a board-certified ...

"There isn't, and it is unlikely there ever will be, a single approach to long COVID. It's very much about personalised medicine." James Chalmers steps away from the ERJ briefly to discuss the recent Monograph on "COVID-19: An Update", which he co-Guest Edited with Catia Cilloniz ...  Show more